Rigel Pharmaceuticals (RIGL) Competitors $18.88 -0.72 (-3.67%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$18.92 +0.05 (+0.24%) As of 07/11/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RIGL vs. INVA, DVAX, MNKD, OPK, NVAX, GERN, RGLS, MYGN, ZBIO, and EBSShould you be buying Rigel Pharmaceuticals stock or one of its competitors? The main competitors of Rigel Pharmaceuticals include Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Novavax (NVAX), Geron (GERN), Regulus Therapeutics (RGLS), Myriad Genetics (MYGN), Zenas BioPharma (ZBIO), and Emergent Biosolutions (EBS). These companies are all part of the "biotechnology" industry. Rigel Pharmaceuticals vs. Its Competitors Innoviva Dynavax Technologies MannKind OPKO Health Novavax Geron Regulus Therapeutics Myriad Genetics Zenas BioPharma Emergent Biosolutions Innoviva (NASDAQ:INVA) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings. Do insiders and institutionals believe in INVA or RIGL? 99.1% of Innoviva shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 2.3% of Innoviva shares are owned by insiders. Comparatively, 9.5% of Rigel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the media prefer INVA or RIGL? In the previous week, Innoviva had 1 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 4 mentions for Innoviva and 3 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 1.17 beat Innoviva's score of 1.11 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, INVA or RIGL? Innoviva has higher revenue and earnings than Rigel Pharmaceuticals. Innoviva is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnoviva$358.71M3.29$23.39M-$1.01-18.58Rigel Pharmaceuticals$179.28M1.88$17.49M$2.079.12 Which has more risk and volatility, INVA or RIGL? Innoviva has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Is INVA or RIGL more profitable? Rigel Pharmaceuticals has a net margin of 18.31% compared to Innoviva's net margin of -16.15%. Innoviva's return on equity of 15.77% beat Rigel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Innoviva-16.15% 15.77% 8.41% Rigel Pharmaceuticals 18.31%-655.26%24.47% Do analysts prefer INVA or RIGL? Innoviva presently has a consensus price target of $40.50, indicating a potential upside of 115.77%. Rigel Pharmaceuticals has a consensus price target of $36.40, indicating a potential upside of 92.80%. Given Innoviva's stronger consensus rating and higher probable upside, research analysts clearly believe Innoviva is more favorable than Rigel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innoviva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Rigel Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 SummaryInnoviva beats Rigel Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RIGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RIGL vs. The Competition Export to ExcelMetricRigel PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$350.30M$2.74B$5.62B$9.10BDividend YieldN/A1.79%5.24%4.00%P/E Ratio9.129.4228.1320.27Price / Sales1.88714.13428.6398.72Price / Cash18.17165.3637.4658.16Price / Book99.374.608.045.49Net Income$17.49M$31.26M$3.18B$250.45M7 Day Performance-0.19%4.80%3.62%4.78%1 Month Performance-11.36%5.42%4.05%7.67%1 Year Performance89.18%-4.36%30.00%16.43% Rigel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RIGLRigel Pharmaceuticals3.0075 of 5 stars$18.88-3.7%$36.40+92.8%+96.3%$350.30M$179.28M9.12160INVAInnoviva4.2145 of 5 stars$20.09+0.7%$55.00+173.8%+11.9%$1.26B$358.71M-19.89100Positive NewsAnalyst ForecastAnalyst RevisionDVAXDynavax Technologies4.3709 of 5 stars$9.92+0.1%$24.00+141.9%+0.7%$1.19B$277.25M-19.08350MNKDMannKind2.4278 of 5 stars$3.74-0.5%$10.33+176.3%-32.8%$1.14B$297.60M37.40400OPKOPKO Health4.1446 of 5 stars$1.32flat$2.75+108.3%-1.5%$1.05B$713.10M-18.852,997News CoverageAnalyst UpgradeNVAXNovavax4.3501 of 5 stars$6.30-1.1%$17.00+169.8%-47.2%$1.02B$682.16M2.381,990GERNGeron3.372 of 5 stars$1.41-5.4%$5.06+259.0%-72.3%$898.06M$76.99M-6.7170News CoverageAnalyst ForecastGap DownRGLSRegulus Therapeutics1.5177 of 5 stars$8.16flat$8.50+4.2%N/A$564.92MN/A-11.1830MYGNMyriad Genetics4.6236 of 5 stars$5.31+1.1%$14.38+170.9%-79.4%$489.48M$837.60M-4.742,700News CoveragePositive NewsZBIOZenas BioPharma1.9232 of 5 stars$9.69+1.1%$36.67+278.4%N/A$405.37M$15M-2.73N/AEBSEmergent Biosolutions4.2654 of 5 stars$6.38+0.5%$14.33+124.7%-25.7%$346.31M$1.04B-2.352,420 Related Companies and Tools Related Companies Innoviva Alternatives Dynavax Technologies Alternatives MannKind Alternatives OPKO Health Alternatives Novavax Alternatives Geron Alternatives Regulus Therapeutics Alternatives Myriad Genetics Alternatives Zenas BioPharma Alternatives Emergent Biosolutions Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RIGL) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rigel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
